Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Shinsuke SasadaNaoto KondoHiroya HashimotoYuko TakahashiKaori TerataKumiko KidaYasuaki SagaraTakayuki UenoKeisei AnanAkihiko SutoChizuko KanbayashiMina TakahashiRikiya NakamuraToshiyuki IshibaMichiko TsuneizumiSeiichiro NishimuraYoichi NaitoFumikata HaraTadahiko ShienHiroji IwataPublished in: Breast cancer research and treatment (2023)
The prognosis was favorable in patients with ER-positive and HER2-negative T1a/bN0M0 breast cancer. Furthermore, adjuvant ET reduced the incidence of distant metastasis with minimal absolute risk difference. These findings support considering the omission of adjuvant ET, especially for patients with low-grade and no lymphatic invasion disease.